Results 41 to 50 of about 18,040 (170)

Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?

Human Vaccines & Immunotherapeutics, 2018
There are two internationally available WHO-prequalified oral rotavirus vaccines (Rotarix and RotaTeq), two rotavirus vaccines licensed in India (Rotavac and Rotasiil), one in China (Lanzhou lamb rotavirus vaccine) and one in Vietnam (Rotavin-M1), and ...
Jacqueline Deen, Anna Lena Lopez, Suman Kanungo, Xuan-Yi Wang, Dang Duc Anh, Milagritos Tapia, Rebecca F. Grais   +6 more
doaj   +1 more source

Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006-2010. [PDF]

PLoS ONE, 2013
Rotavirus vaccines are highly effective at preventing gastroenteritis in young children and are now universally recommended for infants in the US. We studied patterns of use of rotavirus vaccines among US infants with commercial insurance.
Catherine A Panozzo, Sylvia Becker-Dreps, Virginia Pate, Michele Jonsson Funk, Til Stürmer, David J Weber, M Alan Brookhart   +6 more
doaj   +1 more source

Bivalent rotavirus VP4∗ stimulates protective antibodies against common genotypes of human rotaviruses

iScience, 2022
Summary: Non-replicating rotavirus vaccines are an alternative strategy to improve the efficacy and safety of rotavirus vaccines. The spike protein VP4, which could be enzymatically cleaved into VP8∗ and VP5∗, is an ideal target for the development of ...
Guoxing Luo, Yuanjun Zeng, Han Yang, Yijian Li, Lianwei Yang, Cao Li, Feibo Song, Shiyin Zhang, Tingdong Li, Shengxiang Ge, Jun Zhang, Ningshao Xia   +11 more
doaj   +1 more source

Preclinical and clinical development of preventive rotavirus vaccines: special considerations

Биопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. Vaccination is recognised as the only effective method for preventing rotavirus disease. Rotavirus remains a leading cause of death in young children, mainly, in developing countries.
A. S. Korovkin, D. V. Gorenkov, A. A. Soldatov, V. A. Merkulov   +3 more
doaj   +1 more source

Rotavirus vaccines: an overview [PDF]

Clinical Microbiology Reviews, 1996
Rotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial "Jennerian" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against ...
K, Midthun, A Z, Kapikian
openaire   +2 more sources

Secreted Nonstructural Protein 3 is a Pathogenic Determinant of Orbivirus

Advanced Science, EarlyView.
This study uncovers a conserved PIP2‐dependent secretory pathway of orbivirus NS3 that induces vascular leakage. Pharmacological disruption of PIP2‐NS3 interaction significantly reduces viral pathogenicity and provides protective efficacy in murine models, establishing PIP2‐mediated NS3 secretion as both a key virulence determinant and a promising ...
Junyong Guan, Dong Zhou, Ran Shao, Xing Liu, Jin Peng, Yingran Huang, Shuhui Qi, Cankun Xi, Menghang Wang, Bin Sun, Yinglin Qi, Xin Yin   +11 more
wiley   +1 more source

A Novel Rotavirus Reverse Genetics Platform Supports Flexible Insertion of Exogenous Genes and Enables Rapid Development of a High-Throughput Neutralization Assay

Viruses, 2023
Despite the success of rotavirus vaccines, rotaviruses remain one of the leading causes of diarrheal diseases, resulting in significant childhood morbidity and mortality, especially in low- and middle-income countries. The reverse genetics system enables
Jiajie Wei, Scott Radcliffe, Amanda Pirrone, Meiqing Lu, Yuan Li, Jason Cassaday, William Newhard, Gwendolyn J. Heidecker, William A. Rose II, Xi He, Daniel Freed, Michael Citron, Amy Espeseth, Dai Wang   +13 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Trends in hospitalizations for vaccine‐preventable diseases in the United States from 2014 to 2024

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Vaccination rates have declined in recent years, resulting in outbreaks of vaccine‐preventable diseases (VPDs) among children. We aimed to evaluate VPD hospitalization rates from 2014 to 2024 and to report associated trends in outcomes including intensive care utilization, mortality, readmissions, and costs.
Nathan M. Money, Erin Sullivan, Hannah Rector, Corrie E. McDaniel, Jessica L. Markham, Mersine A. Bryan   +5 more
wiley   +1 more source

Options for improving effectiveness of rotavirus vaccines in developing countries

Human Vaccines & Immunotherapeutics, 2017
Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries.
Marion S. Tissera, Daniel Cowley, Nada Bogdanovic-Sakran, Melanie L. Hutton, Dena Lyras, Carl D. Kirkwood, Jim P. Buttery   +6 more
doaj   +1 more source